ALK Australia and TOGA Announce Partnership in New Grant
ALK Positive Australia Inc. and the Thoracic Oncology Group of Australia (TOGA) are honoured to announce a new grant partnership dedicated to advancing ALK+ NSCLC research in Australia for 2025!
TOGA Announces New Board of Director
We are pleased to announce some exciting changes to the TOGA Board of Directors.
Post-ASCO Recap
Post ASCO did an excellent job of showcasing what must’ve been a plethora of lung cancer studies presented at ASCO 2024. Here are a summary of the presentations from A/Prof Thomas John, A/Prof Jaclyn Yoong, and A/Prof Steven Kao.
The Inspirational Research Effect
The process of how new cancer treatments become available and equitable for all Australians and how you can be part of the process to access new medicine.
How do I Access New Cancer Treatments in Australia?
The process of how new cancer treatments become available and equitable for all Australians and how you can be part of the process to access new medicine.
Run with Team TOGA at City2Surf
Team TOGA is gearing up once again for the Sun Herald City2Surf. Join the team to run or walk Sydney’s iconic 14km course from the CBD to Bondi Beach on Sunday 11 August 2024.
TOGA’s Scientific Committee Meeting Recap – May 2024
This meeting provided a full slate with 9 concepts submitted. The concepts spanned the interest areas of every working group and we thank those who take their time to contribute to our peer- and consumer-review process in these groups.
Angeline Low: I am alive! Thanks to Research and Resilience
The Australian Government announced a record-breaking $1.89 billion investment in health and medical research, with a strong focus on improving the lives of Australians living with cancer.
TOGA welcomes $1.89bn for Medical Research Future Fund
The Australian Government announced a record-breaking $1.89 billion investment in health and medical research, with a strong focus on improving the lives of Australians living with cancer.
Build a Winning Business Case for a Lung Cancer Nurse
Lung cancer remains a leading cause of death, and nurses specialising in this area play a critical role in patient care. However, securing funding for a new Lung Cancer Clinical Nurse Specialist (CNS) position requires a persuasive business case.
